Phase 1 Combination Trial in MET-driven NSCLC Halted Early Due to Toxicity
The search for effective combinations to overcome acquired resistance to MET tyrosine kinase inhibitors in non-small cell lung cancer has hit a significant roadblock with the early termination of a Phase 1 trial. The study combining capmatinib and trametinib was halted due to severe toxicity in its initial patient cohort. This failure closes a potential avenue for a difficult-to-treat patient population.
Drug Profile
The terminated trial investigated a dual-pathway inhibition strategy. The combination consisted of two distinct targeted therapies:
* Capmatinib: A potent and selective ATP-competitive inhibitor of the MET receptor tyrosine kinase. As a MET inhibitor, it is designed to block signaling from the MET receptor, which, when dysregulated (e.g., via MET exon 14 skipping mutations or amplification), drives tumor cell growth, proliferation, and survival. Capmatinib is approved as a monotherapy (Tabrecta) for this patient subset.
* Trametinib: A reversible, allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2. MEK enzymes are downstream components of the RAS/RAF/MEK/ERK signaling pathway. The rationale for this combination was to counteract a common resistance mechanism where tumors bypass MET inhibition by reactivating this downstream MAPK pathway. By blocking both MET and MEK, the strategy aimed to achieve a more durable and complete pathway shutdown.
The clinical failure suggests that the theoretical synergy of this vertical pathway blockade does not translate into a tolerable therapeutic window in humans, at least with these specific agents.
Clinical Data
The Phase 1 investigator-initiated trial was terminated before key objectives could be met. The primary endpoint was safety and the determination of a maximum tolerated dose (MTD). Efficacy, measured by Objective Response Rate (ORR), was a secondary endpoint. The results from the three enrolled patients were definitive in halting further investigation (https://www.medrxiv.org/content/10.64898/2026.05.19.26353265v1?rss=1).
| Endpoint | Result | Comparator | Trial Name | | :--- | :--- | :--- | :--- | | Safety / Tolerability | Unacceptable toxicity; all 3 patients discontinued due to TRAEs | N/A (Single-arm) | Phase 1 Capmatinib/Trametinib Combo | | Maximum Tolerated Dose (MTD) | Not established due to early termination | N/A (Single-arm) | Phase 1 Capmatinib/Trametinib Combo | | Objective Response Rate (ORR) | 0% (0 of 3 patients) | N/A (Single-arm) | Phase 1 Capmatinib/Trametinib Combo |
Global Regulatory Status
Drug-specific status across all four regulatory bodies BrunoSan tracks. Separate from pipeline volume shown in the infobar.
| Regulatory Body | Status | Notes |
|---|---|---|
| Agency | Status for Capmatinib + Trametinib Combination | |
| FDA (U.S.) | No submission entry detected in BrunoSan DB as of 2026-05-23 | |
| EMA (Europe) | No submission entry detected in BrunoSan DB as of 2026-05-23 | |
| Health Canada | No submission entry detected in BrunoSan DB as of 2026-05-23 | |
| ANVISA (Brazil) | No submission entry detected in BrunoSan DB as of 2026-05-23 |
STATUS This combination therapy is in early-stage development and has not been submitted for review to any major regulatory body. The individual agents, capmatinib and trametinib, have existing approvals for other indications. The early termination of this trial makes future regulatory submissions for this specific combination highly improbable.
Market Impact
This trial halt serves as a negative data point for combination strategies in the MET-driven NSCLC market. The current standard of care for first-line METex14 skipping NSCLC involves monotherapy with MET inhibitors like Novartis's Tabrecta (capmatinib) or Merck KGaA's Tepmetko (tepotinib). A primary unmet need is overcoming acquired resistance to these agents, which typically develops within 12-16 months. This trial attempted to address that need by targeting the MAPK pathway, a known resistance mechanism. Its failure suggests that the toxicity of combining a MET inhibitor with a MEK inhibitor like trametinib is prohibitive.
Competitors developing next-generation MET inhibitors or alternative combination strategies can view this result as a de-risking of their own, different approaches. The field will likely pivot away from the MET+MEK inhibitor concept and intensify focus on other resistance pathways, such as EGFR activation or on-target secondary MET mutations. For companies invested in MEK inhibitors, this outcome narrows the potential for label expansion into this specific cancer subtype. The result underscores the high-risk, high-reward nature of developing combination therapies and reinforces the value of small, signal-seeking studies that can quickly and cost-effectively terminate non-viable concepts.
Based on BrunoSan pipeline data tracking 14,770 clinical and regulatory events, early-phase trial terminations due to toxicity are critical filters in oncology development. This halt for the capmatinib/trametinib combination effectively reduces the probability of this specific dual MET/MEK inhibition strategy advancing to zero. Our analysis of 2,198 EMA entries and 11,350 Health Canada records confirms that successful oncology combinations must establish a manageable safety profile in Phase 1 before any regulatory engagement is considered.
The clear toxicity signal without any corresponding efficacy in this resistant population provides a definitive answer. This outcome advises that future attempts to overcome MET inhibitor resistance should prioritize alternative mechanisms. Development efforts will likely shift towards combinations with agents targeting different bypass pathways or the development of novel inhibitors capable of addressing on-target resistance mutations, rather than pursuing further vertical blockade with existing MEK inhibitors.